Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates anti-tumor efficacy in CLDN18.2-positive cancers, suggesting a safer treatment option.
AHT-102, a novel Fab-like bispecific antibody, achieves an optimized therapeutic balance through its low-affinity CD3 arm and Fc-free format. It demonstrates significant anti-tumor efficacy and exceptional targeting specificity while avoiding systemic immunotoxicity typically associated with CD3-targeting agents. These findings provide a robust scientific rationale for the clinical translation of AHT-102 in patients with CLDN18.2-positive cancers.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: